Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries - Summary - MDSpire
Advertisement
Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries
To evaluate the real-world effectiveness and safety of blinatumomab in adult patients with measurable residual disease–positive (MRD+) or relapsed/refractory (R/R) Philadelphia chromosome–negative (Ph−) B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), highlighting the significance of these conditions in treatment outcomes.
Key Findings:
In the MRD+ group, 81.8% achieved an MRD response, with a median disease-free survival (DFS) of 31.2 months, indicating a strong treatment effect.
In the R/R group, 82.0% achieved complete remission (CR), with a median relapse-free survival (RFS) of 15.9 months, suggesting effective management of this patient population.
Higher response rates and improved survival outcomes were associated with earlier blinatumomab use, reinforcing the need for timely intervention.
Treatment-related adverse events (TR-TEAEs) occurred in 68.9% of patients, with grade ≥3 TR-TEAEs in 34.5%, necessitating careful monitoring.
Interpretation:
Blinatumomab demonstrates high efficacy in achieving remission and MRD response in both MRD+ and R/R BCP-ALL patients, with earlier treatment correlating with better outcomes, which may influence clinical practice.
Limitations:
The study is retrospective and observational, which may introduce bias, and potential confounding factors should be acknowledged.
The patient population may not fully represent all demographics of BCP-ALL patients, limiting generalizability.
Conclusion:
Blinatumomab is effective and safe for treating adult patients with MRD+ and R/R BCP-ALL, with significant remission rates and a manageable safety profile, underscoring its role in current treatment strategies.
